The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
about
Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular backgroundTargeting EZH2 in cancerHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyTargeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesEZH2 as a mediator of treatment resistance in melanomaEpigenetic determinants of metastasisDietary Flavones as Dual Inhibitors of DNA Methyltransferases and Histone MethyltransferasesEstrogens in Male PhysiologyLoss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Indicators of responsiveness to immune checkpoint inhibitorsEZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant MelanomaTargeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.Aberrant expression of ALK and EZH2 in Merkel cell carcinomaNifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanomaTargeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancerSuppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and ProgressionLoss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.Role of EZH2 histone methyltrasferase in melanoma progression and metastasisSomatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaThin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.Context-dependent actions of Polycomb repressors in cancer.Transcription factors that interact with p53 and Mdm2Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis.Histone variants and melanoma: facts and hypotheses.Mutations and deletions of PRC2 in prostate cancer.Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.Structure of the PRC2 complex and application to drug discovery.
P2860
Q26745416-F47C36C7-6523-437D-A252-6D063148E6ADQ26769027-E5C660F9-E3EB-4461-9C51-97250C59EAE5Q26783032-557A155B-8CB6-47C7-BFFE-D185003C339CQ27853201-D50A8579-835D-4CA8-9916-892B2ED785D4Q28074492-6C8A3F7D-A04B-495E-BC5E-66545B8D3F2FQ28079377-4CF53F06-D013-4EA9-AC28-3596E3F3618DQ28554315-B0ECBFF4-D96E-48ED-84C7-014BD7D0EDF5Q30090708-19D2FFB7-CD0D-4987-897B-17E5408C7FB9Q30313615-0172304B-759D-4C6A-AD0D-32EE005CA612Q33678048-5D5713D0-6433-4913-843C-9486DA0D8D24Q33804215-A3387AF2-0CBC-47BB-88E9-3855C1A764EEQ33809465-FB878402-33D0-4E3A-A57E-B29823638779Q33914216-BDFA019E-97DC-46AD-B2C5-CE5F666C393EQ35815596-3CADB628-9612-45FB-A669-CB0A78F89B37Q35896475-892E9768-0435-4249-B5D2-6A1F0A33FFA2Q36328692-10C48FE2-28C6-4ED2-9CC1-90990F953154Q36528249-928817C9-9411-4611-8438-21A3E284629DQ36545265-B7D7B12F-6E1A-433E-8F10-A2DF9C3E4046Q36562226-84A10A0E-8693-443C-8581-1586CCC8C444Q36772162-BB0621E7-424D-4EB1-A2D3-1BCB429AC751Q36784394-EF39F9C1-4A27-4B5B-9AD4-51FF2BACD044Q36940306-ED3B6825-9155-47AC-A309-622599DB47FDQ37187733-69C4B4CD-635E-4765-8720-E974776AC858Q37218158-43895B68-7C09-434C-BB8C-35E7930C5910Q37327493-7BE68A28-120F-4D04-A194-15356A6FB2DFQ37417271-7ADC8C87-401D-40EE-A163-A517BD7254BFQ37523103-CE35042F-49E9-47CB-8790-DA83C6C3A06EQ37697207-2308FC37-AEA7-4F6E-9360-E32ED937A594Q38518851-DC7BE8A0-8E1B-4835-A66B-C282A2A51394Q38541481-A5B2DE65-CA67-4C55-BF54-CC75AB3961D2Q38547122-D829A9C5-E5C6-4FDC-990C-289BDA8A226FQ38594002-DA79491F-8903-4F63-865A-572DADF6E9D3Q38651948-B0CE9E0F-C09F-4D44-8407-C6ED30367A77Q38748010-08D3D898-A117-44D0-B563-6BC9B59A0952Q38783694-3DC1582E-BA46-4BE6-9980-D70DCADA2D0BQ38906194-399BC9FB-99AC-42DE-86D1-461F42C100EEQ38906678-44007FB2-C26B-482C-A217-EF20785EBE87Q38975402-665585E5-D00B-4554-9CF6-2C7CE5C6A415Q39141421-1EE431D5-CD42-4A4B-B47C-0E1D43A85356Q39245946-F488808B-699E-4B8F-B209-0E0386622771
P2860
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@ast
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@en
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@nl
type
label
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@ast
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@en
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@nl
prefLabel
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@ast
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@en
The epigenetic modifier EZH2 c ...... f distinct tumour suppressors.
@nl
P2093
P2860
P50
P356
P1476
The epigenetic modifier EZH2 c ...... of distinct tumour suppressors
@en
P2093
Caretha L Creasy
Eylul Tuncer
Jessica Haeusel
Julien Debbache
Mario Bonalli
Michael T McCabe
Mitchell P Levesque
Olga Shakhova
Raffaella Santoro
Reinhard Dummer
P2860
P2888
P356
10.1038/NCOMMS7051
P407
P577
2015-01-22T00:00:00Z
P5875
P6179
1016502955